StockData
Verastem, Inc. logo

Verastem, Inc. (VSTM) company profile

VSTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$7.41−0.29 (-3.77%)

Close on Nov 17, 2026Market cap $671.08MP/E –Yield –

About Verastem

Pharmaceutical Preparations, SIC 2834

Verastem is a biopharmaceutical company that develops and commercializes targeted cancer therapeutics directed at the RAS/MAPK signaling pathway. The company's primary commercial offering is AVMAPKI FAKZYNJA CO-PACK, an oral combination of avutometinib and defactinib. Its clinical development pipeline also features VS-7375, an oral inhibitor under evaluation for solid tumors such as pancreatic, non-small cell lung, and colorectal cancers. Verastem provides its therapies to adult patients diagnosed with recurrent low-grade serous ovarian cancer following prior systemic treatment, serving healthcare providers, academic medical institutions, and community oncology practices through specialized distributors and pharmacies.

Commercial sales are concentrated in the United States, where the business distributes treatments through specialty pharmacies and distributors. Clinical research operations involve patients and investigative sites across multiple international territories, including the United States, Australia, Canada, Europe, the United Kingdom, and Japan, alongside collaboration activities in China. The provided text does not disclose the location of the company's headquarters.

Summary of the business section of Verastem's latest annual report, written by StockData.

Company profile

Company

Legal name
Verastem, Inc.
Founded
2010
Headquarters
Needham, MA
Address
117 Kendrick Street, Suite 500 02494
Phone
(781) 292-4200
Employees
102, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Massachusetts
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
VSTM
Exchange
Nasdaq
IPO date
Jan 27, 2012
Shares outstanding
91M, Aug 3, 2026
Public float
$253.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Jun 1, 2023
SEC CIK
1526119
CUSIP
92337C203
ISIN
US92337C2035
FIGI
BBG001J2LSK5
Share class FIGI
BBG001V0G978
LEI
549300IY0EFBIU8NQC81
EIN
27-3269467

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Dan PatersonPresident and CEO, Director844,542
Michael KauffmanPresident of Development, Director8,666
Daniel CalkinsChief Financial Officer123,781
Matthew RosChief Operating Officer50,000
Michael P. BaileyDirector108,000
Michelle RobertsonDirector52,666
Paul A. BunnDirector44,333
Karin Anna TollefsonDirector52,666
Eric K. RowinskyDirector54,666
John JohnsonDirector52,666
Brian M. StuglikDirector137,147
Anil KapurDirector52,666
Robert E. GagnonDirector41,678

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.35M$3.78M$958.34K$160–
FY2024$2.54M$2.38M$741.01K$107–
FY2023
Mr.Brian Stuglik
$2.02M$2.20M$622.56K$169–
FY2023
Mr.Daniel Paterson
$3.63M$3.24M$622.56K$169–
FY2022$1.03M-$1.33M$487.59K$20–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Daniel Paterson
President and Chief Executive Officer
$674.00K$1.16M–$489.32K$24.99K$2.35M-7%
Matthew Ros
Former Chief Operating Officer
$455.15K$585.33K–$196.43K$388.25K$1.63M–
Daniel Calkins
Chief Financial Officer
$350.00K$450.72K–$151.20K$24.95K$976.87K+32%
Michael Kauffman
President of Development
$30.00K$62.33K$75.66K–$105.00K$272.99K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 27, 2012
Offer price
$10.00
Securities offered
5,500,000
Gross proceeds
$55.00M
Exchange
Nasdaq
First trading day
Jan 27, 2012
First-day close
$11.09+10.9%
Lock-up ends (est.)
Jul 25, 2012

“Per share Total Public offering price $ 10.00 $ 55,000,000 Underwriting discounts and commissions $ 0.70 $ 3,850,000 Proceeds to Verastem, before expenses $ 9.30 $ 51,150,000 Certain of our existing stockholders and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximate”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 102 full time equivalent employees, including a total of 23 employees with M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?